Biora Therapeutics, INC 8-K filings

Biora Therapeutics has commenced a Chapter 11 sale process to strengthen its balance sheet and advance product development, supported by up to $10.25 million in new financing.

Biora Therapeutics will be delisted from the Nasdaq due to non-compliance with market value requirements and will begin trading on the OTC Markets.

Biora Therapeutics has received a delisting notice from Nasdaq due to its market value of publicly held shares falling below the required threshold, despite being granted an extension to regain compliance with a separate market value rule.

Biora Therapeutics announced a strategic shift towards licensing its BioJet device, along with Q3 2024 financial results and an extension to regain Nasdaq compliance.

Biora Therapeutics has completed a registered direct offering of common stock and warrants, raising approximately $3 million in gross proceeds.

Biora Therapeutics has approved a 1-for-10 reverse stock split and a reduction in authorized shares, effective October 18, 2024.

Biora Therapeutics closed a $4 million funding round and exchanged existing debt for new payment priority notes on October 7, 2024.

Biora Therapeutics closed a $4 million funding round and exchanged existing debt for new payment priority notes on September 10, 2024.

Biora Therapeutics and Ravgen, Inc. have reached a settlement in their ongoing litigation, with Ravgen agreeing to dismiss its claims and no payments being made by either party.

Biora Therapeutics closed a debt exchange and secured new funding totaling $14.76 million through a convertible notes transaction.

Biora Therapeutics reports successful Phase 1 clinical trial results for its BT-600 drug delivery system and secures $16 million in funding from existing investors.

Biora Therapeutics has entered into financing agreements with existing convertible note holders for a $16 million multiple-draw facility to support operations until a potential pharmaceutical partnership is secured.

Biora Therapeutics' BT-600 Phase 1 trial shows successful targeted drug delivery to the colon using the NaviCap device, with lower systemic exposure and promising tissue concentrations.

Biora Therapeutics reports successful Phase 1 clinical trial results for BT-600, demonstrating targeted drug delivery to the colon using its NaviCap platform.

Biora Therapeutics has entered into an agreement to potentially sell up to $90 million of its common stock through an at-the-market offering, with an initial offering of up to $6 million.

Biora Therapeutics has received a delisting notice from Nasdaq after failing to maintain the required market value of listed securities, and plans to appeal the decision.

Biora Therapeutics' stockholders approved an increase in authorized shares of common stock at the 2024 Annual Meeting, alongside the election of directors and ratification of the company's accounting firm.

Biora Therapeutics announced the completion of its BT-600 clinical trial, progress in its BioJet platform partnering, and first quarter 2024 financial results, including a net loss of $4.2 million.

Biora Therapeutics has entered into a securities purchase agreement for a registered direct offering of common stock and warrants, expected to close on April 3, 2024, to raise approximately $6 million.

Biora Therapeutics announced positive results from its BT-600 clinical trial, demonstrating targeted drug delivery, and reported its fourth quarter and full-year 2023 financial results.

Biora Therapeutics has successfully reduced its net debt and secured $5.8 million in funding through a convertible note exchange and the sale of a legacy asset.

Biora Therapeutics has announced its 2024 outlook, highlighting key milestones for its NaviCap and BioJet platforms, including clinical study results and progress with pharmaceutical collaborations.